SIGA Technologies, Inc.  

(Public, OTCMKTS:SIGA)   Watch this stock  
Find more results for NASDAQ:SIGA
1.00
0.00 (0.00%)
Apr 29 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.95 - 1.00
52 week 0.20 - 2.06
Open 1.00
Vol / Avg. 81,370.00/94,387.00
Mkt cap 54.11M
P/E     -
Div/yield     -
EPS -0.73
Shares 54.11M
Beta 1.42
Inst. own 14%

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -479.70% -482.53%
Operating margin -474.67% -474.14%
EBITD margin - -199.35%
Return on average assets -42.10% -22.41%
Return on average equity - -
Employees 29 -
CDP Score - -

Address

660 Madison Ave Ste 1700
NEW YORK, NY 10065-8446
United States - Map
+1-212-6729100 (Phone)
+1-212-6973130 (Fax)

Website links

Description

SIGA Technologies, Inc. (SIGA) is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company's lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). Tecovirimat is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. Tecovirimat has Orphan Drug designation for both the treatment and prevention of smallpox, and the treatment of orthopoxvirus infections (vaccinia, variola, monkeypox and cowpox). The Company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture Tecovirimat. The Company also has a lead pre-clinical drug candidate with activity against approximately four serotypes of the dengue virus.

Officers and directors

Eric A. Rose M.D. Chairman of the Board, Chief Executive Officer
Age: 64
Daniel J. Luckshire Chief Financial Officer, Executive Vice President, Secretary
Age: 44
Dennis E. Hruby Ph.D. Chief Scientific Officer, Vice President
Age: 63
James J. Antal CPA Independent Director
Age: 64
Michael Jonathan Bayer Independent Director
Age: 66
Thomas E. Constance Independent Director
Age: 79
Jeffrey B. Kindler Independent Director
Age: 60
Joseph W. Marshall III Independent Director
Age: 62